Sep. 4 at 12:00 AM
$WVE
Today’s update: Wave (
$WVE) released new AATD data (WVE-006). The stock sold off sharply as the market focused on weaker 200 mg single-dose results, overlooking encouraging signs from multi-dose and higher-dose cohorts.
• WVE-006 results: Reduction in mutant protein, increase in protective wild-type protein, and proof RNA editing works in patients.
• Comparison:
$BEAM still superior – higher M-AAT purity, stronger Z-AAT knockdown, and one-and-done DNA edit durability.
• RNA advantage: Despite BEAM’s lead, WVE’s RNA delivery and safety/tunability profile remain compelling and could differentiate long-term.
• Insider note: WVE CEO sold ~217k shares late Aug under a 10b5-1 plan before release.
• My move: While the biology looks encouraging, BEAM remains best-in-class. I’ve cut my
$WVE position by ~60%, still holding some shares in case 400 mg multi-dose data closes the gap.
• Next catalyst: Watch for 400 mg multi-dose cohort readout – this will be the real test if WVE can rival BEAM.
